Fulcrum Therapeutics

Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN

FDA · IgAN · 6 min

This week, the biotech sector saw a wave of regulatory and business development activity: PHG and KMDA won FDA approvals, FULC halted its pociredir program, RMD closed the Noctrix acquisition, and NVS posted positive data in IgAN. We break down what each event means for pharma teams and investors.

FDA Concerns About Cancer Risk Sink Fulcrum Therapeutics’ Sickle Cell Disease Drug: Implications for SCD Pipeline and BD Strategy

FDA · sickle cell disease · 4 min

Fulcrum Therapeutics is discontinuing its lead sickle cell disease drug, pociredir, after the FDA raised concerns about cancer risk. The decision, which sent shares down 52%, reshapes the SCD competitive landscape and opens strategic questions for pipeline watchers and BD teams.

Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation

Food and Drug Administration · sickle cell disease · 5 min

Fulcrum Therapeutics' stock experienced a significant 54% drop following the discontinuation of its sickle cell disease drug, citing regulatory hurdles. This event highlights potential challenges in clinical trial design for the indication.

Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures

FDA · sickle cell · 6 min

A ten-year-old Cambridge-based biotech company is actively seeking a merger or acquisition. This move comes as public markets have shown volatility, impacting biotech valuations.

Fulcrum Explores Sale Amid FDA Setback for Sickle Cell Drug

FDA · sickle cell disease · 6 min

Fulcrum Therapeutics is reportedly exploring strategic alternatives, including a potential sale, after the FDA raised concerns about its lead sickle cell drug, pociredir. This move follows similar market withdrawals for other sickle cell treatments.

New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights

9 min

A novel radiopharmaceutical is demonstrating promising results in patients who have previously been treated with Pluvicto, signaling a potential shift in the advanced prostate cancer treatment paradigm. This development presents significant competitive implications for companies like Abivax, Fulcrum, Convergent, and Vera.